{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:46:40Z","timestamp":1792082800063,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00262-022-03295-1","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T10:03:08Z","timestamp":1664186588000},"page":"895-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification"],"prefix":"10.1007","volume":"72","author":[{"given":"Motaz","family":"Ashkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi Swaroop","family":"Vege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"3295_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1053\/j.gastro.2018.01.031","volume":"154","author":"SS Vege","year":"2018","unstructured":"Vege SS, DiMagno MJ, Forsmark CE, Martel M, Barkun AN (2018) Initial medical treatment of acute pancreatitis: American gastroenterological association institute technical review. Gastroenterology 154:1103\u20131139","journal-title":"Gastroenterology"},{"key":"3295_CR2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1053\/j.gastro.2018.01.032","volume":"154","author":"SD Crockett","year":"2018","unstructured":"Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN (2018) American gastroenterological association institute guideline on initial management of acute pancreatitis. Gastroenterology 154:1096\u20131101","journal-title":"Gastroenterology"},{"key":"3295_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","volume":"62","author":"PA Banks","year":"2013","unstructured":"Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG et al (2013) Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus. Gut 62:102\u2013111","journal-title":"Gut"},{"key":"3295_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R et al (2019) Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7:31","journal-title":"J Immunother Cancer"},{"key":"3295_CR5","doi-asserted-by":"publisher","first-page":"djw260","DOI":"10.1093\/jnci\/djw260","volume":"109","author":"CF Friedman","year":"2017","unstructured":"Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK et al (2017) Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 109:djw260","journal-title":"J Natl Cancer Inst"},{"key":"3295_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S et al (2019) Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 11:225\u2013236","journal-title":"J Clin Med Res"},{"key":"3295_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"3295_CR8","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4:560\u2013575","journal-title":"Transl Lung Cancer Res"},{"key":"3295_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","volume":"25","author":"C Hsu","year":"2020","unstructured":"Hsu C, Marshall JL, He AR (2020) Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment. Oncologist 25:105\u2013111","journal-title":"Oncologist"},{"key":"3295_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","volume":"19","author":"P Cramer","year":"2017","unstructured":"Cramer P, Bresalier RS (2017) Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19:3","journal-title":"Curr Gastroenterol Rep"},{"key":"3295_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"MK Callahan","year":"2018","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM et al (2018) Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 36:391\u2013398","journal-title":"J Clin Oncol"},{"key":"3295_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/CMR.0000000000000611","volume":"29","author":"J Kohlmann","year":"2019","unstructured":"Kohlmann J, Wagenknecht D, Simon JC, Ziemer M (2019) Immune-related pancreatitis associated with checkpoint blockade in melanoma. Melanoma Res 29:549\u2013552","journal-title":"Melanoma Res"},{"key":"3295_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","volume":"41","author":"JM Michot","year":"2018","unstructured":"Michot JM, Ragou P, Carbonnel F, Champiat S, Voisin AL, Mateus C, Lambotte O et al (2018) Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication. J Immunother 41:84\u201385","journal-title":"J Immunother"},{"key":"3295_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"3295_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","volume":"19","author":"J George","year":"2019","unstructured":"George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C et al (2019) Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology 19:587\u2013594","journal-title":"Pancreatology"},{"key":"3295_CR16","doi-asserted-by":"publisher","first-page":"1027323","DOI":"10.1155\/2018\/1027323","volume":"2018","author":"Q Su","year":"2018","unstructured":"Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW (2018) Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res 2018:1027323","journal-title":"J Immunol Res"},{"key":"3295_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","volume":"5","author":"G Widmann","year":"2016","unstructured":"Widmann G, Nguyen VA, Plaickner J, Jaschke W (2016) Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep 5:59","journal-title":"Curr Radiol Rep"},{"key":"3295_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clinimag.2020.04.007","volume":"64","author":"R Thomas","year":"2020","unstructured":"Thomas R, Sebastian B, George T, Majeed NF, Akinola T, Laferriere SL, Braschi-Amirfarzan M (2020) A review of the imaging manifestations of immune check point inhibitor toxicities. Clin Imaging 64:70\u201379","journal-title":"Clin Imaging"},{"key":"3295_CR19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with Ipilimumab. Cancer Immunol Res 3:1185\u20131192","journal-title":"Cancer Immunol Res"},{"key":"3295_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/imt-2017-0126","volume":"10","author":"T Prasanna","year":"2018","unstructured":"Prasanna T, McNeil CM, Nielsen T, Parkin D (2018) Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy 10:171\u2013175","journal-title":"Immunotherapy"},{"key":"3295_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.clinbiochem.2017.07.003","volume":"50","author":"OZ Ismail","year":"2017","unstructured":"Ismail OZ, Bhayana V (2017) Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem 50:1275\u20131280","journal-title":"Clin Biochem"},{"key":"3295_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03295-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:48:58Z","timestamp":1679881738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03295-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03295-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Motaz Ashkar, Shruti Chandra, Hiroaki Takahash, Naoki Takahashi, Santhi Swaroop Vege\u2014no conflict of interest to disclose and no project-related funding support. Robert R. McWilliams\u2014Zentalis Pharmaceuticals advisor, no project-related funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}